Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Adocia SA (A89.F) Follow Compare 4.9550 +0.0650 +(1.33%) At close: February 21 at 8:17:50 AM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for A89.F 1D 5D -8.75% 1M -18.37% 3M -38.98% 6M -10.56% YTD -14.86% 1Y -48.22% 5Y -55.36% All -66.89% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: A89.F View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Number of Shares and Voting Rights of ADOCIA as of January 31st, 2025 ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets Number of Shares and Voting Rights of ADOCIA as of December 31st, 2024 ADOCIA Announces Its Participation at Upcoming Investor Conferences in 2025 ADOCIA Announces its Financial Calendar for 2025 ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment Number of Shares and Voting Rights of ADOCIA as of November 30th, 2024 Number of Shares and Voting Rights of ADOCIA as of October 31st, 2024 ADOCIA Reports Third Quarter 2024 Financial Results and Provides a Business Update ADOCIA Announces Patenting Stable Combinations of GLP-1 and Amylin Analogs for the Treatment of Obesity and Diabetes Using Its BioChaperone® Platform Number of Shares and Voting Rights of ADOCIA as of September 30th, 2024 Related Tickers 0M4.SG Mersana Therapeutics Inc 0.4837 -3.88% 0M4.F Mersana Therapeutics, Inc. 0.4502 -2.58% 0M4.MU Mersana Therapeutics Inc 0.5106 -7.60% SYRS Syros Pharmaceuticals, Inc. 0.1743 -0.85% MRSN Mersana Therapeutics, Inc. 0.5332 +0.98% MRNA Moderna, Inc. 35.53 +5.34%